The Myeloproliferative Neoplasms Research Consortium (MPN-RC), funded by the National Cancer Institute (NCI), has launched a new website showcasing our innovative laboratory and clinical research to cure MPNs. You can find information on our collaborative efforts to translate findings from our laboratory based studies into novel clinical trials to evaluate treatments for patients living with MPNs. Visit MPN-RC to read more about our exciting research and our leaders who are spearheading this important research and subscribe for updates.

The Myeloproliferative Neoplasm Quality of Life Study Group, headed by Dr. Ruben Mesa of the Mays Cancer Center, is a collaboration amongst leading MPN physicians and researchers from some of the most prestigious institutions in the world, including the Mays Cancer Center at UT Health San Antonio MD Anderson, Arizona State University, University of Arizona, University of California Irvine, and the Mayo Clinic.  Check out their website today! or their latest newsletter!

Since 2013, the MPN Heroes Recognition Program has recognized the people and organizations that have dedicated themselves to improving the lives of people with MPNs. The program focuses on the three “classical” MPNs—or what are known as Philadelphia chromosome–negative MPNs.

2022 marks the tenth anniversary of the MPN Heroes Recognition Program, sponsored by Incyte Corporation and CURE magazine. Our goal is to create as many opportunities as possible for people with MPNs to be heard and to be supported, so more solutions and treatment options will emerge.

Created in the spirit of fostering community, the program recognizes patients, Healthcare Professionals, caregivers, advocates, and organizations that contribute to bringing understanding, compassion, and strength to the MPN community.  Nominate your hero today!

Stories about 3 patients (Antje with ET, Annette with PV and Bill with MF) on the NORD website.